Heart failure medicine was linked to lower dementia risk
Sacubitril/valsartan use was associated with less dementia in people with heart failure. Missing study-design details prevent a causal interpretation.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
This review asked whether sacubitril/valsartan use in people with heart failure was associated with greater dementia risk. Instead, the pooled findings linked its use to lower risk of dementia from any cause than comparison treatments. Because the abstract does not describe the underlying study designs, this association cannot establish that the medicine prevents dementia.
The abstract omits follow-up lengths, individual study designs and absolute dementia rates. This abstract-based summary cannot determine the absolute risk difference or explain how the association arose.
What researchers found
Dementia from any cause
Sacubitril/valsartan versus placebo, no treatment or other heart failure medicines; follow-up duration not reported. Pooled risk ratio: 0.85 (95% confidence interval: 0.74-0.98).
Relative risk has limits
The finding describes dementia risk relative to the comparison groups. It does not describe an absolute percentage-point reduction. Without absolute dementia rates, the abstract cannot show the difference in the number of people affected.
Checking the combined result
The authors repeated analyses while leaving out individual studies and also examined subgroups. They reported consistent findings, but these checks do not supply missing study-design information or establish that the medicine caused the lower dementia risk.
The original publication
Sacubitril/Valsartan Reduces the Risk of All-Cause Dementia in Patients with Heart Failure: A Systematic Review and Meta-Analysis.
Helal MM, Almosilhy NA, Hamam NG et al.
Drugs Aging · 2025
- PubMed ID
- 40728824
- Record checked
Linked publication notices
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.